Belite Bio, Inc Share Price Deutsche Boerse AG
Equities
D01
US07782B1044
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.8 EUR | -.--% | +7.18% | -.--% |
14/05 | Transcript : Belite Bio, Inc, Q1 2024 Earnings Call, May 14, 2024 | |
14/05 | Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | - | Sales 2025 * | 10M 9.22M 834M | Capitalization | 1.46B 1.34B 122B |
---|---|---|---|---|---|
Net income 2024 * | -31M -28.58M -2.59B | Net income 2025 * | -25M -23.05M -2.09B | EV / Sales 2024 * | - |
Net cash position 2024 * | 84.92M 78.31M 7.08B | Net cash position 2025 * | 49.8M 45.92M 4.15B | EV / Sales 2025 * | 141 x |
P/E ratio 2024 * |
-46.7
x | P/E ratio 2025 * |
-58
x | Employees | 20 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99% |
Latest transcript on Belite Bio, Inc
1 week | +7.18% | ||
Current month | +0.90% | ||
1 month | +21.74% |
Managers | Title | Age | Since |
---|---|---|---|
Yue Hsin Lin
CEO | Chief Executive Officer | 46 | 27/18/27 |
Hao Yuan Chuang
DFI | Director of Finance/CFO | 40 | 01/20/01 |
Nathan L. Mata
CTO | Chief Tech/Sci/R&D Officer | 58 | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 72 | 01/22/01 | |
Yi Ta Lue
BRD | Director/Board Member | 47 | 01/22/01 |
John Longo
BRD | Director/Board Member | 55 | 01/22/01 |
Date | Price | Change |
---|---|---|
31/24/31 | 44.4 | -0.89% |
30/24/30 | 44.8 | +4.19% |
29/24/29 | 43 | +3.37% |
28/24/28 | 41.6 | +0.97% |
27/24/27 | 41.2 | -1.44% |
Delayed Quote Deutsche Boerse AG, May 01, 2024 at 01:25 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- BLTE Stock
- D01 Stock